HopeStage
Back to overview

ADHD studies

Topics
More filters

ADHD

Attention-deficit/hyperactivity disorder (ADHD) involves persistent difficulties with attention, impulsivity or restlessness that can affect everyday life.

1811studies shown
Showing 1,333-1,344 of 1,811
Drug study icon
CompletedNCT00499863

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

What is this study about?

Researchers compared methylphenidate transdermal system and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.

This study has finished and is no longer accepting participants.

Multiple locations, including Scottsdale
ADHDMedication studyAges 13–17
Countries
United States
Sponsor
Noven Therapeutics
Drug study icon
CompletedNCT03247556

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

What is this study about?

Researchers compared 400mg SPN-812, 600mg SPN-812 and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.

This study has finished and is no longer accepting participants.

Multiple locations, including Long Beach
ADHDMedication studyAges 12–17
Countries
United States
Sponsor
Supernus Pharmaceuticals, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT03247543

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

Official study title

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) 200 and 400 mg Efficacy and Safety in Children With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial

This study has finished and is no longer accepting participants.

Multiple locations, including Long Beach
ADHDMedication studyAges 6–11
Countries
United States
Sponsor
Supernus Pharmaceuticals, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT03247517

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

What is this study about?

Researchers compared 200mg SPN-812, 400mg SPN-812 and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.

This study has finished and is no longer accepting participants.

Multiple locations, including Dothan
ADHDMedication studyAges 12–17
Countries
United States
Sponsor
Supernus Pharmaceuticals, Inc. (Pharmaceutical company)
Other study type icon
CompletedNCT03283579

Fatty Acids and Attention Deficit and Hyperactivity Disorder Symptoms

Official study title

Prenatal Omega-6/Omega-3 Ratio and Attention Deficit and Hyperactivity Disorder Symptoms in Children: a Population-based Longitudinal Study

This study has finished and is no longer accepting participants.

Location not clearly listed
ADHDObservational studyAges 4–8
Countries
Sponsor
Barcelona Institute for Global Health

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.